Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Oracle Shares Tumble Amid Investor Concerns Over AI Execution

Andreas Sommer by Andreas Sommer
December 14, 2025
in AI & Quantum Computing, Earnings, Nasdaq, Tech & Software
0
Oracle Stock
0
SHARES
27
VIEWS
Share on FacebookShare on Twitter

Oracle Corporation’s stock is navigating turbulent trading sessions. A recent media report alleging delays in a critical OpenAI project injected fresh volatility on Friday, compounding existing investor unease following the company’s latest quarterly results. Despite swift management rebuttals, a sell-off ensued, highlighting growing market skepticism about the aggressive timeline for its artificial intelligence infrastructure expansion.

Record Contracts and Mounting Capital Demands

The current volatility follows Oracle’s recent financial disclosure, which presented a complex picture. The software giant reported an explosive surge in its remaining performance obligations (RPO), which soared to a record $523 billion. This growth is primarily fueled by massive cloud contracts with AI leaders, including Nvidia and Meta.

However, fulfilling these commitments requires immense upfront investment. Oracle has significantly raised its capital expenditure (CapEx) forecast to $50 billion. These substantial outlays pressured its free cash flow deeply into negative territory last quarter, a development that has drawn scrutiny from financial analysts. The central question emerging on Wall Street is the timeline for converting this enormous backlog into profitable revenue.

A Denial Fails to Stem the Selling Pressure

The immediate catalyst for Friday’s decline was a Bloomberg report suggesting the completion of a planned data center for OpenAI could be delayed until 2028, citing supply chain and labor constraints. Oracle promptly issued a denial, stating no such delays exist and that all project milestones remain on schedule.

Should investors sell immediately? Or is it worth buying Oracle?

The market’s reaction, however, was pronounced. Oracle’s equity closed the session down 4.67 percent at €161.44. The sell-off indicates deep-seated investor apprehension about execution risks associated with the company’s massive physical infrastructure build-out.

Diverging Analyst Views on Valuation and Strategy

This episode reflects broader doubts about the near-term payoff from AI investments. Oracle’s stock has undergone a significant valuation correction, now trading more than 42 percent below its 52-week high.

Expert commentary is divided. Some market strategists have lowered their price targets, citing the high capital intensity and potential for deferred revenue recognition. Others view the current financial pressures as a necessary cost of securing long-term dominance in the competitive cloud sector.

For shareholders, the coming quarters will be critical in assessing Oracle’s ability to advance its infrastructure expansion without further margin erosion. Income-focused investors are looking ahead to January 9, 2026, the key date for the company’s next quarterly dividend distribution.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from March 25 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

SOXX ETF Stock
Commodities

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock
Analysis

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Figma Stock
AI & Quantum Computing

Figma Embraces Third-Party AI to Power Its Design Ecosystem

March 25, 2026
Next Post
Fortive Stock

Fortive Shares Face Selling Pressure Following Major Investor Exit

Omv Stock

OMV's Upstream Division Delivers a Strategic One-Two Punch

Solana Stock

Institutional Investors Accumulate Solana Amidst Price Weakness

Recommended

Lockheed Martin Stock

Defense Giant Lockheed Martin Secures Billions in New Military Contracts

6 months ago
OKE stock news

Amalgamated Bank Increases Stake in CF Industries as Market Opinions Vary

3 years ago
IBM Stock

IBM’s AI Windfall Fails to Impress Stock Market

7 months ago
Blackstonecured Lending Fund Stock

Blackstone BDC Insider Purchase Defies Analyst Downgrades

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Figma Embraces Third-Party AI to Power Its Design Ecosystem

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

Evolent Health Bets on AI Leadership Amid Share Price Decline

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Trending

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

by Kennethcix
March 25, 2026
0

The future of Gossamer Bio hinges on a critical regulatory discussion scheduled for June 2026. The biopharmaceutical...

SOXX ETF Stock

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Figma Stock

Figma Embraces Third-Party AI to Power Its Design Ecosystem

March 25, 2026
BioNano Genomics Stock

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026
  • Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns
  • Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com